Nipocalimab for Lupus Nephritis
Recruiting0 awardsPhase 2
Glendale, Arizona
This trial is testing nipocalimab, a medicine that reduces harmful antibodies, in patients with active Lupus Nephritis, a severe kidney condition caused by lupus. The study will last over a year and will monitor safety and effectiveness.
Monoclonal Antibodies
Ravulizumab for Lupus Nephritis and IgA Nephropathy
Recruiting0 awardsPhase 2
Los Angeles, California
This trial is testing the safety and effectiveness of a drug called ravulizumab, given through a vein, in patients with specific kidney diseases. The drug aims to reduce kidney damage by blocking part of the immune system.
CAR T-cell Therapy
CAR T-Cell Therapy for Lupus Nephritis
Recruiting1 awardPhase 1 & 2
Denver, Colorado
This trial is testing a new treatment that uses modified immune cells to target and destroy harmful cells in adults with severe kidney inflammation from lupus that doesn't respond to usual treatments.
Cell Therapy
AB-101 + B-cell Depleting mAb for Lupus Nephritis
Recruiting1 awardPhase 1
San Diego, California
This trial is testing a new cell product called AB-101, which contains natural killer cells that can enhance the effect of antibody therapies. The trial will enroll adults with lupus nephritis who have not
Popular Filters
Trials for LN Patients
Anti-metabolites
Mycophenolate Mofetil for Pediatric Lupus Nephritis
Recruiting1 awardPhase 2
Chicago, Illinois
This trial is a 1-year study with two parts. It is double-blinded, meaning neither the participants nor the researchers know which treatment they are receiving. The trial is comparing two different treatment approaches
Iptacopan for Lupus Nephritis
Recruiting0 awardsPhase 2
Phoenix, Arizona
This trial is testing a new medication called iptacopan to see if it can help patients when added to their usual treatments. It targets patients who are already receiving standard care and aims to make their current treatments work better.
Monoclonal Antibodies
VIB4920 for Lupus Nephritis
Recruiting0 awardsPhase 2
La Jolla, California
This trial is testing a new drug called VIB4920, along with two other medications, MMF and prednisone, to treat kidney problems caused by lupus. The study involves people who have active lupus nephritis, a serious kidney condition. The treatment aims to reduce inflammation and calm the immune system to help improve kidney function. MMF has been established as an effective treatment for lupus nephritis, often used in combination with other medications like prednisone.
Monoclonal Antibodies
Anifrolumab for Lupus Nephritis
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial is testing an IV medication called anifrolumab in adults with severe lupus nephritis. The goal is to see if it can reduce inflammation and prevent kidney damage. All patients will also receive standard treatments. Anifrolumab is approved by the FDA for treating moderate to severe systemic lupus erythematosus (SLE).
Monoclonal Antibodies
Ianalumab + Standard Therapy for Lupus Nephritis
Recruiting1 awardPhase 3
Fairfax, Virginia
This trial will test how well ianalumab injections work and how safe they are for adults with a type of kidney inflammation caused by lupus. The medication is given under the skin at regular intervals. It aims to reduce kidney inflammation by calming the immune system.
Trials for Lupus Patients
Monoclonal Antibodies
CABA-201 for Lupus
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial tests a new cell therapy called CABA-201 for patients with active lupus. It aims to help those whose disease is not well-controlled by current treatments. Patients first get standard medications to prepare their bodies, then receive CABA-201 to help manage their immune system.
Trials for Anti-dsDNA Positive Patients
CAR T-cell Therapy
NKX019 + Cyclophosphamide for Lupus Nephritis
Recruiting1 awardPhase 1
Atlanta, Georgia
This trial will test a new treatment called NKX019 in participants with lupus kidney disease. The study will focus on assessing the safety and how well the treatment is tolerated by the participants.
Monoclonal Antibodies
CABA-201 for Lupus
Recruiting1 awardPhase 1 & 2
Boston, Massachusetts
This trial tests a new cell therapy called CABA-201 for patients with active lupus. It aims to help those whose disease is not well-controlled by current treatments. Patients first get standard medications to prepare their bodies, then receive CABA-201 to help manage their immune system.
Immunomodulator
Povetacicept for Autoimmune Kidney Diseases
Recruiting1 awardPhase 1 & 2
Phoenix, Arizona
This trial will assess if a drug (povetacicept) is safe & potentially beneficial in treating IgA nephropathy, membranous nephropathy & lupus nephritis. Participants receive drug every 4 weeks for 6 months, with the possibility of a 6-month extension.
CAR T-cell Therapy
Rapcabtagene Autoleucel for Lupus Nephritis
Recruiting1 awardPhase 2
Chicago, Illinois
"This trial aims to compare the effectiveness and safety of rapcabtagene autoleucel with the standard treatment in patients with lupus and kidney inflammation that has not responded to standard treatment."
Trials With No Placebo
Anti-metabolites
Mycophenolate Mofetil for Pediatric Lupus Nephritis
Recruiting1 awardPhase 2
Chicago, Illinois
This trial is a 1-year study with two parts. It is double-blinded, meaning neither the participants nor the researchers know which treatment they are receiving. The trial is comparing two different treatment approaches
Monoclonal Antibodies
Daratumumab for Lupus Nephritis
Recruiting1 awardPhase 2
Rochester, Minnesota
This trial is testing daratumumab, a medication that helps the immune system, in patients with active lupus nephritis. The goal is to see if it can help these patients by reducing kidney damage caused by their disease.
CAR T-cell Therapy
NKX019 + Cyclophosphamide for Lupus Nephritis
Recruiting1 awardPhase 1
Atlanta, Georgia
This trial will test a new treatment called NKX019 in participants with lupus kidney disease. The study will focus on assessing the safety and how well the treatment is tolerated by the participants.
Anti-metabolites
ADI-001 for Lupus Nephritis
Recruiting1 awardPhase 1
Manhasset, New York
This trial is testing a new treatment for lupus nephritis in multiple centers. It will involve different stages like screening, treatment, and follow-up to find the appropriate dose and assess its safety and effectiveness
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.